Related Experiment Video
Updated: Feb 4, 2026
10:02
Whole-body PET/MRI of Pediatric Patients: The Details That Matter
Published on: December 19, 2017
15.3K
Enterovirus infections in pediatric hematologic/oncologic patients
Volker Strenger1, Harald H Kessler2, Evelyn Stelzl2
1Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.
Pediatric Blood & Cancer
|October 2, 2018
Summary
Enterovirus (EV) infections are rare in pediatric cancer patients, typically showing no symptoms. Most patients clear EV RNA, indicating a low clinical impact in this vulnerable population.
Area of Science:
- Virology
- Pediatric Oncology
- Infectious Diseases
Background:
- Enteroviruses (EV) are Picornaviruses linked to various symptoms in healthy individuals.
- Limited data exists on the impact of enteroviruses in pediatric hematologic/oncologic patients.
Purpose of the Study:
- To investigate the epidemiologic and clinical significance of enterovirus infections in pediatric hematologic/oncologic patients.
Main Methods:
- Clinical specimens were collected from pediatric hematologic/oncologic patients between 2001 and 2017.
- Specimens were tested for the presence of enteroviral RNA.
Main Results:
- Enteroviral RNA was detected in 0.3% of specimens (1.8% of patients).
- No EV RNA was found in cerebrospinal fluid from patients with neurological symptoms.
- Most patients (11/14) tested negative for EV RNA in follow-up specimens; one patient with severe immune deficiency had persistent RNA for over 5 years.
Conclusions:
- Enterovirus infections are uncommon and asymptomatic in this pediatric cohort.
- EV RNA detection can be inconsistent between specimens from the same patient.
- Enterovirus infections appear to have a minimal clinical impact on pediatric hematologic/oncologic patients.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
264
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
264
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
311
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
311
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
233
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
233
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
301
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
301
01:20Infection
12.6K
When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
12.6K
01:26Stages of Infection
65.3K
Stages of infection describe what happens to a susceptible host once a pathogen invades the human body. The stages of infection are incubation, prodromal, illness, stage of decline, and convalescence. The incubation stage is the period from exposure to a pathogen until symptoms start. The infected person is unaware of impending illness as the pathogens grow and multiply within the body. The duration may vary depending on the type of infection. The incubation period of measles averages ten to...
65.3K